	US 12,441,982 B2
	Pharmaceutical composition containing neprilysin-overexpressing stem cell, conditioned medium thereof, and exosome isolated therefrom as active ingredient for prevention or treatment of cognitive impairment
Yun Bae Kim, Sejong-si (KR); Ehn Kyoung Choi, Daejeon (KR); and Tae Myoung Kim, Cheongju-si (KR)
Assigned to DESIGNED CELLS CO., LTD., Cheongju-si (KR)
Filed by DESIGNED CELLS CO.,LTD., Cheongju-si (KR)
Filed on Sep. 30, 2022, as Appl. No. 17/937,096.
Claims priority of application No. 10-2021-0129385 (KR), filed on Sep. 30, 2021; and application No. 10-2022-0109195 (KR), filed on Aug. 30, 2022.
Prior Publication US 2023/0096790 A1, Mar. 30, 2023
Int. Cl. C12N 5/073 (2010.01); A61P 25/28 (2006.01)

CPC C12N 5/0605 (2013.01) [A61P 25/28 (2018.01); C12N 2500/76 (2013.01)]

5 Claims

1. A method for preventing, alleviating, or treating cognitive impairment, the method comprising steps of culturing stem cells in a medium containing a Panax plant extract to obtain a neprilysin-overexpressing stem cell, and

administering to a subject in need thereof at least one selected from the group consisting of the neprilysin-overexpressing stem cell, a conditioned medium thereof, and an exosome isolated therefrom,

wherein the cognitive impairment is a disease in which the expression or aggregation level of amyloid beta is higher or at risk of being higher than normal, and wherein the Panax plant is at least one selected from the group consisting of red ginseng and cultivated wild ginseng.